IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v24y2006i12p1173-1177.html
   My bibliography  Save this article

Do Pharmacogenomic Tests Provide Value to Policy Makers?

Author

Listed:
  • Ya-Chen Shih
  • Lajos Pusztai

Abstract

No abstract is available for this item.

Suggested Citation

  • Ya-Chen Shih & Lajos Pusztai, 2006. "Do Pharmacogenomic Tests Provide Value to Policy Makers?," PharmacoEconomics, Springer, vol. 24(12), pages 1173-1177, December.
    • Handle: RePEc:spr:pharme:v:24:y:2006:i:12:p:1173-1177
    DOI: 10.2165/00019053-200624120-00002
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/00019053-200624120-00002
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/00019053-200624120-00002?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Karl Claxton, 1999. "Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals," Health Economics, John Wiley & Sons, Ltd., vol. 8(3), pages 269-274, May.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Edward C. F. Wilson & Miranda Mugford & Garry Barton & Lee Shepstone, 2016. "Efficient Research Design," Medical Decision Making, , vol. 36(3), pages 335-348, April.
    2. Niklas Zethraeus & Magnus Johannesson & Bengt Jönsson & Mickael Löthgren & Magnus Tambour, 2003. "Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies," PharmacoEconomics, Springer, vol. 21(1), pages 39-48, January.
    3. Claire McKenna & Karl Claxton, 2011. "Addressing Adoption and Research Design Decisions Simultaneously," Medical Decision Making, , vol. 31(6), pages 853-865, November.
    4. Heikkinen, T. & Pietola, K., 2009. "Investment and the dynamic cost of income uncertainty: The case of diminishing expectations in agriculture," European Journal of Operational Research, Elsevier, vol. 192(2), pages 634-646, January.
    5. Joshua Graff Zivin, 2001. "Cost‐effectiveness analysis with risk aversion," Health Economics, John Wiley & Sons, Ltd., vol. 10(6), pages 499-508, September.
    6. Castillo-Riquelme, Marianela & Chalabi, Zaid & Lord, Joanne & Guhl, Felipe & Campbell-Lendrum, Diarmid & Davies, Clive & Fox-Rushby, Julia, 2008. "Modelling geographic variation in the cost-effectiveness of control policies for infectious vector diseases: The example of Chagas disease," Journal of Health Economics, Elsevier, vol. 27(2), pages 405-426, March.
    7. Mark Strong & Jeremy E. Oakley & Alan Brennan & Penny Breeze, 2015. "Estimating the Expected Value of Sample Information Using the Probabilistic Sensitivity Analysis Sample," Medical Decision Making, , vol. 35(5), pages 570-583, July.
    8. Scott B. Cantor, 2004. "Clinical Applications in the Decision Analysis Literature," Decision Analysis, INFORMS, vol. 1(1), pages 23-25, March.
    9. Francisco-José Polo & Miguel Negrín & Xavier Badía & Montse Roset, 2005. "Bayesian regression models for cost-effectiveness analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 45-52, March.
    10. Bognar, Katalin & Romley, John A. & Bae, Jay P. & Murray, James & Chou, Jacquelyn W. & Lakdawalla, Darius N., 2017. "The role of imperfect surrogate endpoint information in drug approval and reimbursement decisions," Journal of Health Economics, Elsevier, vol. 51(C), pages 1-12.
    11. Stefano Conti & Karl Claxton, 2009. "Dimensions of Design Space: A Decision-Theoretic Approach to Optimal Research Design," Medical Decision Making, , vol. 29(6), pages 643-660, November.
    12. Björn Stollenwerk & Stefan K. Lhachimi & Andrew Briggs & Elisabeth Fenwick & Jaime J. Caro & Uwe Siebert & Marion Danner & Andreas Gerber‐Grote, 2015. "Communicating the Parameter Uncertainty in the IQWiG Efficiency Frontier to Decision‐Makers," Health Economics, John Wiley & Sons, Ltd., vol. 24(4), pages 481-490, April.
    13. Haitham Tuffaha & Shelley Roberts & Wendy Chaboyer & Louisa Gordon & Paul Scuffham, 2015. "Cost-Effectiveness and Value of Information Analysis of Nutritional Support for Preventing Pressure Ulcers in High-risk Patients: Implement Now, Research Later," Applied Health Economics and Health Policy, Springer, vol. 13(2), pages 167-179, April.
    14. Álvaro Hidalgo-Vega & Juan Ramos-Goñi & Renata Villoro, 2014. "Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 917-925, December.
    15. P. Sendi & A. Gafni & S. Birch, 2002. "Opportunity costs and uncertainty in the economic evaluation of health care interventions," Health Economics, John Wiley & Sons, Ltd., vol. 11(1), pages 23-31, January.
    16. F. J. Vázquez‐Polo & M. A. Negrín Hernández & B. González López‐Valcárcel, 2005. "Using covariates to reduce uncertainty in the economic evaluation of clinical trial data," Health Economics, John Wiley & Sons, Ltd., vol. 14(6), pages 545-557, June.
    17. A. E. Ades & G. Lu & K. Claxton, 2004. "Expected Value of Sample Information Calculations in Medical Decision Modeling," Medical Decision Making, , vol. 24(2), pages 207-227, March.
    18. Sander Greenland, 2005. "Multiple‐bias modelling for analysis of observational data," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 168(2), pages 267-306, March.
    19. Anna Heath & Petros Pechlivanoglou, 2022. "Prioritizing Research in an Era of Personalized Medicine: The Potential Value of Unexplained Heterogeneity," Medical Decision Making, , vol. 42(5), pages 649-660, July.
    20. K. Claxton & P. J. Neumannn & S. S. Araki & M. C. Weinstein, "undated". "Bayesian Value-of-Information Analysis: An Application to a Policy Model of Alzheimer's Disease," Discussion Papers 00/39, Department of Economics, University of York.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:24:y:2006:i:12:p:1173-1177. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.